Gentian Diagnostics AS

Gentian Diagnostics AS

GENT · OL · Healthcare / Medical Devices

39.80NOK+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close39.80
Open39.20
Day Range39.20 – 39.80
52-Week Range33.50 – 59.20
Volume27.69K
Market Cap602.89M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.55
Dividend Yield1.54%
Beta0.45
50-Day Avg39.05
200-Day Avg42.40

About

Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. It offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Calprotectin Immunoassay, a turbidimetric assay used for the measurement of circulating calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a GFR marker for the diagnosis and therapeutic control of renal function and chronic kidney disease; Gentian Retinol-Binding Protein Immunoassay for detection of retinol-binding protein in human serum and plasma; and Canine CRP Immunoassay test kit, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine C-reactive protein in dog plasma and serum. The company also develops faecal calprotectin immunoassay turbo that offers results of calprotectin concentration in stool supporting diagnosis of inflammatory bowel disease; and faecal pancreatic elastase immunoassay turbo, which allows analysis of pancreatic elastase in stool to aid in diagnosis of pancreatic exocrine insufficiency. Gentian Diagnostics ASA was founded in 2001 and is headquartered in Moss, Norway.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOMr. Matti Heinonen
  • Employees63
  • HeadquartersBjOernAsveien 5, Moss, Norway, 1596, Norway
  • Websitehttps://www.gentian.com

Leadership

  • Mr. Matti HeinonenChief Executive Officer
  • Mr. Njaal KindCFO & COO
  • Mr. Frank FrantzenChief Technology Officer · b. 1957
  • Dr. Aleksandra HavelkaChief Scientific Officer
  • Mr. Markus JaquemarChief Growth Officer
  • Dr. Tom NilsenHead of Product Development

Financials

Income Statement

Currency: NOK2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue22.89M24.55M25.59M30.90M34.99M46.11M47.95M68.37M83.12M101.64M136.19M152.07M176.50M
Growth (%)-+7.25%+4.21%+20.75%+13.24%+31.78%+4.00%+42.58%+21.58%+22.27%+34.00%+11.66%+16.06%
Cost of Revenue5.12M5.01M4.95M7.02M5.79M6.59M25.45M32.59M43.18M52.63M70.91M69.25M78.30M
Gross Profit17.78M19.54M20.64M23.88M29.20M39.52M22.50M35.78M39.95M49.00M65.29M82.82M98.20M
Gross Margin77.64%79.59%80.67%77.29%83.46%85.71%46.93%52.34%48.06%48.21%47.94%54.46%55.64%
Operating Expense16.61M20.69M22.53M33.93M45.40M60.20M49.66M53.61M62.79M72.24M78.05M67.09M72.75M
Operating Income1.17M-1.14M-1.89M-10.06M-16.20M-20.69M-27.15M-17.82M-22.85M-23.23M-12.76M15.72M25.45M
Operating Margin5.09%-4.66%-7.39%-32.55%-46.30%-44.86%-56.63%-26.07%-27.49%-22.86%-9.37%10.34%14.42%
EBITDA1.47M-1.30M-1.56M-6.62M-12.10M-15.77M-21.02M-12.52M-18.38M-15.94M-3.08M31.54M35.45M
EBITDA Margin6.42%-5.29%-6.12%-21.44%-34.59%-34.21%-43.84%-18.32%-22.12%-15.68%-2.26%20.74%20.09%
Net Income873.99K-2.91M-3.22M-8.93M-15.17M-19.80M-39.86M-17.11M-24.79M-24.00M-10.65M45.29M13.26M
Net Income Margin3.82%-11.85%-12.59%-28.89%-43.36%-42.94%-83.12%-25.03%-29.83%-23.61%-7.82%29.78%7.51%
R&D2.25M3.47M3.00M2.15M3.94M3.80M19.21M26.12M26.81M24.69M36.08M21.92M23.16M
R&D as % of Total Revenue9.82%14.12%11.74%6.96%11.26%8.23%40.07%38.21%32.25%24.29%26.49%14.41%13.12%
Interest Expense721.45K749.29K438.27K1.34M19.76K64.39K363.00K550.00K1.45M1.32M871.00K2.52M5.22M
Interest Expense % of Total Revenue3.15%3.05%1.71%4.34%0.06%0.14%0.76%0.80%1.75%1.30%0.64%1.65%2.96%

Balance Sheet

Currency: NOK2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets14.17M19.27M99.96M122.96M205.23M257.98M227.18M235.26M211.79M187.79M181.04M229.66M258.54M
Total Liabilities12.55M11.88M4.90M7.42M8.75M12.11M18.94M40.69M37.02M33.62M34.40M35.61M53.58M
Total Equity1.62M7.39M95.06M115.54M196.48M245.87M208.24M194.58M174.77M154.17M146.64M194.05M204.96M
Cash1.74M1.96M47.92M74.35M145.33M198.31M171.24M157.65M114.94M81.60M87.64M84.74M105.93M
Total Debt9.91M6.08M--466.17K698.00K6.61M22.27M22.70M15.32M13.05M10.04M-
Net Debt8.17M4.11M-47.92M-74.35M-144.87M-197.61M-166.94M-135.37M-96.35M-66.28M-74.59M-74.70M-

Cash Flow

Currency: NOK2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow2.43M-1.95M-4.63M-7.90M-18.63M-10.90M-21.48M-7.66M-27.05M-13.95M15.46M13.46M42.59M
Investing Cash Flow-3.52M-2.39M-4.62M-4.48M-6.91M-6.15M-4.04M-4.57M-12.81M-14.67M-4.88M-10.95M-10.76M
Financing Cash Flow1.47M4.58M75.28M20.40M96.54M68.75M-1.58M-1.51M-3.12M-4.33M-4.60M-4.95M-11.13M
Capital Expenditure3.49M3.59M4.12M7.11M6.91M6.15M4.04M6.47M12.81M14.67M4.49M10.95M10.76M
Free Cash Flow-1.06M-5.54M-8.75M-15.01M-25.54M-17.05M-25.52M-14.13M-39.87M-28.62M10.97M2.51M31.83M
Dividends Paid------------6.17M
FCF to OCF-43.53%284.03%189.11%189.94%137.08%156.47%118.80%184.41%147.37%205.12%70.97%18.63%74.74%
Dividend Paid to FCF------------19.38%

Earnings

Report DateFeb 15, 2017May 9, 2017Aug 23, 2017Nov 15, 2017Feb 27, 2018May 16, 2018Aug 17, 2018Nov 16, 2018Feb 28, 2019May 9, 2019Aug 15, 2019Nov 7, 2019Feb 14, 2020Apr 24, 2020Aug 21, 2020Oct 29, 2020Feb 11, 2021Apr 16, 2021Aug 25, 2021Oct 21, 2021Feb 17, 2022Apr 28, 2022Aug 25, 2022Oct 27, 2022Feb 16, 2023May 5, 2023Aug 24, 2023Oct 26, 2023Feb 9, 2024Apr 30, 2024Aug 29, 2024Oct 31, 2024Feb 12, 2025May 7, 2025Jul 11, 2025Oct 24, 2025Feb 12, 2026May 7, 2026Jul 9, 2026
EPS Estimate------------------0.34-0.30-0.45-0.12-0.200.10-0.37-0.13--------------
EPS Actual-0.25-0.380.03-0.36-0.38-0.28-0.16-0.04-0.85-0.47-1.32-0.34-0.46-0.36-0.09-0.45-0.23-0.23-0.23-0.44-0.62-0.43-0.19-0.61-0.30-0.040.06-0.05-0.630.270.300.212.090.49-0.130.260.22-1.320.29
Surprise-----------------32.35%23.33%2.22%-416.67%-115.00%-290.00%-64.86%-130.77%--------------
TimingAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market--Pre-marketPre-marketPre-market-Pre-marketPre-market-----

Key Statistics & Ratios

Market Cap602.89M
Enterprise Value512.53M
Trailing P/E0.00
Forward P/E0.00
Price / Sales3.31
Price / Book3.15
EPS-0.55
Book Value11.82
Revenue (TTM)182.12M
Gross Profit (TTM)101.09M
EBITDA25.90M
Profit Margin-4.62%
Operating Margin11.88%
Return on Equity-4.42%
Return on Assets6.30%
Shares Outstanding15.46M
Shares Float7.28M
Beta0.45
Dividend Yield1.54%
Dividend Rate0.60
Payout Ratio46.51%

Dividends

20261×
0.60May 6, 2026
20251×
0.40May 7, 2025